Berkeley Capital Partners LLC decreased its stake in shares of GlaxoSmithKline PLC (NYSE:GSK) by 11.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,395 shares of the pharmaceutical company’s stock after selling 921 shares during the period. Berkeley Capital Partners LLC’s holdings in GlaxoSmithKline PLC were worth $319,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. 10 15 Associates Inc. raised its stake in GlaxoSmithKline PLC by 6.4% in the first quarter. 10 15 Associates Inc. now owns 237,716 shares of the pharmaceutical company’s stock valued at $10,022,000 after buying an additional 14,247 shares in the last quarter. Lincluden Management Ltd. raised its stake in GlaxoSmithKline PLC by 1.7% in the first quarter. Lincluden Management Ltd. now owns 120,845 shares of the pharmaceutical company’s stock valued at $5,095,000 after buying an additional 1,990 shares in the last quarter. Anchor Capital Advisors LLC raised its stake in GlaxoSmithKline PLC by 9.6% in the first quarter. Anchor Capital Advisors LLC now owns 613,324 shares of the pharmaceutical company’s stock valued at $25,858,000 after buying an additional 53,894 shares in the last quarter. BlueCrest Capital Management Ltd raised its stake in GlaxoSmithKline PLC by 293.5% in the first quarter. BlueCrest Capital Management Ltd now owns 51,157 shares of the pharmaceutical company’s stock valued at $2,157,000 after buying an additional 38,157 shares in the last quarter. Finally, Roundview Capital LLC raised its stake in GlaxoSmithKline PLC by 157.4% in the first quarter. Roundview Capital LLC now owns 24,529 shares of the pharmaceutical company’s stock valued at $1,034,000 after buying an additional 15,000 shares in the last quarter. 8.96% of the stock is owned by institutional investors.

GlaxoSmithKline PLC (NYSE:GSK) opened at 38.79 on Friday. The stock has a 50 day moving average price of $41.84 and a 200 day moving average price of $41.84. The stock has a market cap of $94.80 billion, a P/E ratio of 37.51 and a beta of 1.03. GlaxoSmithKline PLC has a 12-month low of $37.20 and a 12-month high of $44.59.

GlaxoSmithKline PLC (NYSE:GSK) last posted its quarterly earnings data on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.68 by $0.02. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. On average, analysts forecast that GlaxoSmithKline PLC will post $2.85 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be given a $0.491 dividend. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 dividend on an annualized basis and a yield of 5.06%. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s dividend payout ratio is 197.00%.

TRADEMARK VIOLATION WARNING: “GlaxoSmithKline PLC (GSK) Shares Sold by Berkeley Capital Partners LLC” was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.dailypolitical.com/2017/08/12/glaxosmithkline-plc-gsk-shares-sold-by-berkeley-capital-partners-llc.html.

GSK has been the subject of several research analyst reports. Zacks Investment Research lowered GlaxoSmithKline PLC from a “hold” rating to a “sell” rating in a research note on Monday, April 17th. J P Morgan Chase & Co reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 13th. Berenberg Bank raised GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. TheStreet raised GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. Finally, Citigroup Inc. reaffirmed a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Thursday, July 27th. Two analysts have rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $46.00.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline PLC (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.